The crystalloid versus hydroxyethyl starch trial: Protocol for a multi-centre randomised controlled trial of fluid resuscitation with 6% hydroxyethyl starch (130/0.4) compared to 0.9% sodium chloride (saline) in intensive care patients on mortality

John Myburgh, Rinaldo Bellomo, Alan Cass, Julie French, Simon Finfer, David Gattas, Parisa Glass, Joanne Lee, Jeffrey Lipman, Bette Liu, Colin McArthur, Shay McGuinness, Dorrilyn Rajbhandari, Colman Taylor, Steve Webb

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The intravenous fluid 6% hydroxyethyl starch (130/0.4) (6% HES 130/0.4) is used widely for resuscitation but there is limited information on its efficacy and safety. A large-scale multi-centre randomised controlled trial (CHEST) in critically ill patients is currently underway comparing fluid resuscitation with 6% HES 130/0.4 to 0.9% sodium chloride on 90-day mortality and other clinically relevant outcomes including renal injury. This report describes the study protocol. CHEST will recruit 7,000 patients to concealed, random, parallel assignment of either 6% HES 130/0.4 or 0.9% sodium chloride for all fluid resuscitation needs whilst in the intensive care unit (ICU). The primary outcome will be all-cause mortality at 90 days post-randomisation. Secondary outcomes will include incident renal injury, other organ failures, ICU and hospital mortality, length of ICU stay, quality of life at 6 months, health economic analyses and in patients with traumatic brain injury, functional outcome. Subgroup analyses will be conducted in four predefined subgroups. All analyses will be conducted on an intention-to-treat basis. The study run-in phase has been completed and the main trial commenced in April 2010. CHEST should generate results that will inform and influence prescribing of this commonly used resuscitation fluid.

Original languageEnglish
Pages (from-to)816-823
Number of pages8
JournalIntensive Care Medicine
Volume37
Issue number5
DOIs
Publication statusPublished - 1 May 2011
Externally publishedYes

Keywords

  • Colloids
  • Fluid therapy
  • Hydroxyethyl starch
  • Randomised controlled trials
  • Resuscitation

Cite this

@article{2072fc00d95d4e25a6157b4d1740b514,
title = "The crystalloid versus hydroxyethyl starch trial: Protocol for a multi-centre randomised controlled trial of fluid resuscitation with 6{\%} hydroxyethyl starch (130/0.4) compared to 0.9{\%} sodium chloride (saline) in intensive care patients on mortality",
abstract = "The intravenous fluid 6{\%} hydroxyethyl starch (130/0.4) (6{\%} HES 130/0.4) is used widely for resuscitation but there is limited information on its efficacy and safety. A large-scale multi-centre randomised controlled trial (CHEST) in critically ill patients is currently underway comparing fluid resuscitation with 6{\%} HES 130/0.4 to 0.9{\%} sodium chloride on 90-day mortality and other clinically relevant outcomes including renal injury. This report describes the study protocol. CHEST will recruit 7,000 patients to concealed, random, parallel assignment of either 6{\%} HES 130/0.4 or 0.9{\%} sodium chloride for all fluid resuscitation needs whilst in the intensive care unit (ICU). The primary outcome will be all-cause mortality at 90 days post-randomisation. Secondary outcomes will include incident renal injury, other organ failures, ICU and hospital mortality, length of ICU stay, quality of life at 6 months, health economic analyses and in patients with traumatic brain injury, functional outcome. Subgroup analyses will be conducted in four predefined subgroups. All analyses will be conducted on an intention-to-treat basis. The study run-in phase has been completed and the main trial commenced in April 2010. CHEST should generate results that will inform and influence prescribing of this commonly used resuscitation fluid.",
keywords = "Colloids, Fluid therapy, Hydroxyethyl starch, Randomised controlled trials, Resuscitation",
author = "John Myburgh and Rinaldo Bellomo and Alan Cass and Julie French and Simon Finfer and David Gattas and Parisa Glass and Joanne Lee and Jeffrey Lipman and Bette Liu and Colin McArthur and Shay McGuinness and Dorrilyn Rajbhandari and Colman Taylor and Steve Webb",
year = "2011",
month = "5",
day = "1",
doi = "10.1007/s00134-010-2117-9",
language = "English",
volume = "37",
pages = "816--823",
journal = "Intensive Care Medicine",
issn = "0342-4642",
publisher = "Springer-Verlag London Ltd.",
number = "5",

}

The crystalloid versus hydroxyethyl starch trial : Protocol for a multi-centre randomised controlled trial of fluid resuscitation with 6% hydroxyethyl starch (130/0.4) compared to 0.9% sodium chloride (saline) in intensive care patients on mortality. / Myburgh, John; Bellomo, Rinaldo; Cass, Alan; French, Julie; Finfer, Simon; Gattas, David; Glass, Parisa; Lee, Joanne; Lipman, Jeffrey; Liu, Bette; McArthur, Colin; McGuinness, Shay; Rajbhandari, Dorrilyn; Taylor, Colman; Webb, Steve.

In: Intensive Care Medicine, Vol. 37, No. 5, 01.05.2011, p. 816-823.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The crystalloid versus hydroxyethyl starch trial

T2 - Protocol for a multi-centre randomised controlled trial of fluid resuscitation with 6% hydroxyethyl starch (130/0.4) compared to 0.9% sodium chloride (saline) in intensive care patients on mortality

AU - Myburgh, John

AU - Bellomo, Rinaldo

AU - Cass, Alan

AU - French, Julie

AU - Finfer, Simon

AU - Gattas, David

AU - Glass, Parisa

AU - Lee, Joanne

AU - Lipman, Jeffrey

AU - Liu, Bette

AU - McArthur, Colin

AU - McGuinness, Shay

AU - Rajbhandari, Dorrilyn

AU - Taylor, Colman

AU - Webb, Steve

PY - 2011/5/1

Y1 - 2011/5/1

N2 - The intravenous fluid 6% hydroxyethyl starch (130/0.4) (6% HES 130/0.4) is used widely for resuscitation but there is limited information on its efficacy and safety. A large-scale multi-centre randomised controlled trial (CHEST) in critically ill patients is currently underway comparing fluid resuscitation with 6% HES 130/0.4 to 0.9% sodium chloride on 90-day mortality and other clinically relevant outcomes including renal injury. This report describes the study protocol. CHEST will recruit 7,000 patients to concealed, random, parallel assignment of either 6% HES 130/0.4 or 0.9% sodium chloride for all fluid resuscitation needs whilst in the intensive care unit (ICU). The primary outcome will be all-cause mortality at 90 days post-randomisation. Secondary outcomes will include incident renal injury, other organ failures, ICU and hospital mortality, length of ICU stay, quality of life at 6 months, health economic analyses and in patients with traumatic brain injury, functional outcome. Subgroup analyses will be conducted in four predefined subgroups. All analyses will be conducted on an intention-to-treat basis. The study run-in phase has been completed and the main trial commenced in April 2010. CHEST should generate results that will inform and influence prescribing of this commonly used resuscitation fluid.

AB - The intravenous fluid 6% hydroxyethyl starch (130/0.4) (6% HES 130/0.4) is used widely for resuscitation but there is limited information on its efficacy and safety. A large-scale multi-centre randomised controlled trial (CHEST) in critically ill patients is currently underway comparing fluid resuscitation with 6% HES 130/0.4 to 0.9% sodium chloride on 90-day mortality and other clinically relevant outcomes including renal injury. This report describes the study protocol. CHEST will recruit 7,000 patients to concealed, random, parallel assignment of either 6% HES 130/0.4 or 0.9% sodium chloride for all fluid resuscitation needs whilst in the intensive care unit (ICU). The primary outcome will be all-cause mortality at 90 days post-randomisation. Secondary outcomes will include incident renal injury, other organ failures, ICU and hospital mortality, length of ICU stay, quality of life at 6 months, health economic analyses and in patients with traumatic brain injury, functional outcome. Subgroup analyses will be conducted in four predefined subgroups. All analyses will be conducted on an intention-to-treat basis. The study run-in phase has been completed and the main trial commenced in April 2010. CHEST should generate results that will inform and influence prescribing of this commonly used resuscitation fluid.

KW - Colloids

KW - Fluid therapy

KW - Hydroxyethyl starch

KW - Randomised controlled trials

KW - Resuscitation

UR - http://www.scopus.com/inward/record.url?scp=79955566267&partnerID=8YFLogxK

U2 - 10.1007/s00134-010-2117-9

DO - 10.1007/s00134-010-2117-9

M3 - Article

VL - 37

SP - 816

EP - 823

JO - Intensive Care Medicine

JF - Intensive Care Medicine

SN - 0342-4642

IS - 5

ER -